Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control

This report discusses the results of cardiovascular and renal outcomes from the two landmark trials.

https://link.springer.com/10.1007/s13340-018-0367-x

Source: Diabetology International - October 1, 2018 Category: Endocrinology Source Type: research

More News: Canagliflozin | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Invokana | Jardiance | SGLT2 Inhibitors | Sodium | Study | Urinary Tract Infections